|
|
Article: Axonyx Announces Results of Interim Analysis of Beta- Amyloid Trial; Data Meet Pre-Defined Criteria for Continuing Trial Enrollment in Top Dose Group.
- Article from:
- Business Wire
- Article date:
- March 12, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK -- Axonyx Inc. (NASDAQ:AXYX) announced today interim results from the first 37 patients in a Phase IIb double-blind placebo-controlled clinical trial (designated AX-CL-06a) designed to evaluate the effects of Phenserine tartrate (PT) on cerebrospinal fluid (CSF) levels of beta-amyloid (A(beta) 1- 42) and other biomarkers in mild to moderate Alzheimer's Disease (AD) patients. The presence of toxic beta-amyloid in the brains of AD patients is considered by many experts to be a key pathological event in the causation as well as the progression of AD. A reduction of beta-amyloid levels could correlate to a reduced progression of AD. Patients received Phenserine 10mg ...